Unknown

Dataset Information

0

A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia


ABSTRACT: Description A new therapeutic approach for the treatment of a skeletal disorder with AAVs bypasses bone resistance to gene transfer. Adeno-associated virus (AAV) vectors are a well-established gene transfer approach for rare genetic diseases. Nonetheless, some tissues, such as bone, remain refractory to AAV. X-linked hypophosphatemia (XLH) is a rare skeletal disorder associated with increased levels of fibroblast growth factor 23 (FGF23), resulting in skeletal deformities and short stature. The conventional treatment for XLH, lifelong phosphate and active vitamin D analogs supplementation, partially improves quality of life and is associated with severe long-term side effects. Recently, a monoclonal antibody against FGF23 has been approved for XLH but remains a high-cost lifelong therapy. We developed a liver-targeting AAV vector to inhibit FGF23 signaling. We showed that hepatic expression of the C-terminal tail of FGF23 corrected skeletal manifestations and osteomalacia in a XLH mouse model. Our data provide proof of concept for AAV gene transfer to treat XLH, a prototypical bone disease, further expanding the use of this modality to treat skeletal disorders.

SUBMITTER: Zhukouskaya V 

PROVIDER: S-EPMC8550245 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4010385 | biostudies-literature
| S-EPMC3733247 | biostudies-literature
| S-EPMC5697498 | biostudies-literature
| S-EPMC5693779 | biostudies-literature
| S-EPMC4129793 | biostudies-other
| S-EPMC6770816 | biostudies-literature
| S-EPMC9935080 | biostudies-literature
| S-EPMC8318504 | biostudies-literature
| S-EPMC3976884 | biostudies-other